Last reviewed · How we verify
NCT05581797
Psilocybin-assisted Interpersonal Therapy for Depression
NA trial testing Psilocybin-assisted psychotherapy in Depressive Disorder, Treatment-Resistant in 5 participants. Completed in 4 June 2024.
6 May 2024
Quick facts
| Lead sponsor | University of Otago |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 15 March 2023 |
| Primary completion | 6 May 2024 |
| Estimated completion | 4 June 2024 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- Psilocybin-assisted psychotherapy — full drug profile →
Conditions studied
- Depressive Disorder, Treatment-Resistant — all drugs for Depressive Disorder, Treatment-Resistant →
Sponsor
University of Otago
Who can join
Adults 21 to 75, any sex, with Depressive Disorder, Treatment-Resistant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open-label interventional study of psilocybin-assisted interpersonal therapy for treatment resistant depression. 20 participants will be recruited to take part in this 8-week intervention that involves 8 sessions of psychotherapy and 2 doses of psilocybin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05581797
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depressive Disorder, Treatment-Resistant
Currently open trials in the same condition.
- NCT07053345 — A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression · Phase 4 · recruiting
- NCT06668571 — Intravenous Ketamine for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT06511908 — Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resi · Phase 2 · recruiting
- NCT05570344 — rTMS With and Without Text4Support for the Treatment of Resistant Depression. · NA · recruiting
- NCT05641623 — OSU6162 as add-on in SSRI/SNRI-resistant Depression · Phase 2 · recruiting
Other University of Otago trials
Trials by the same sponsor.
- NCT05030909 — Feasibility Study of a Group Intervention for Youth Wellbeing · NA · recruiting
- NCT05576259 — oVRcome - Self Guided Virtual Reality for Social Anxiety Disorder · NA · completed
- NCT05090046 — Understanding Neurocognitive Impairment After Trauma Exposure · completed
- NCT05052333 — Examine the Psychosocial Impacts of COVID-19 Pandemic. · completed
- NCT04909177 — oVRcome Self-guided Virtual Reality for Specific Phobias · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05581797 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Otago
- Last refreshed: 9 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05581797.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing